MY134562A - Methods and compositions to treat conditions associated with neovascularization - Google Patents

Methods and compositions to treat conditions associated with neovascularization

Info

Publication number
MY134562A
MY134562A MYPI20015730A MYPI20015730A MY134562A MY 134562 A MY134562 A MY 134562A MY PI20015730 A MYPI20015730 A MY PI20015730A MY PI20015730 A MYPI20015730 A MY PI20015730A MY 134562 A MY134562 A MY 134562A
Authority
MY
Malaysia
Prior art keywords
neovascularization
compositions
methods
conditions associated
treat conditions
Prior art date
Application number
MYPI20015730A
Other languages
English (en)
Inventor
Kin-Ping Wong
Ming-Chung Wong
Original Assignee
Wackvom Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wackvom Ltd filed Critical Wackvom Ltd
Publication of MY134562A publication Critical patent/MY134562A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MYPI20015730A 2000-12-15 2001-12-14 Methods and compositions to treat conditions associated with neovascularization MY134562A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25587600P 2000-12-15 2000-12-15

Publications (1)

Publication Number Publication Date
MY134562A true MY134562A (en) 2007-12-31

Family

ID=22970220

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20015730A MY134562A (en) 2000-12-15 2001-12-14 Methods and compositions to treat conditions associated with neovascularization

Country Status (7)

Country Link
US (1) US6608107B2 (enExample)
EP (1) EP1343487A2 (enExample)
JP (1) JP2005502579A (enExample)
CN (1) CN100490791C (enExample)
AU (1) AU2002230888A1 (enExample)
MY (1) MY134562A (enExample)
WO (1) WO2002047673A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385936A (en) 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
CA2417500C (en) * 2000-07-28 2008-11-18 Georgetown University Medical Center Erbb-2 selective small molecule kinase inhibitors
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
CN100413493C (zh) * 2003-06-11 2008-08-27 中国科学院动物研究所 棉酚及其衍生物在制备治疗骨髓瘤药物中的应用
DE602004012279T3 (de) * 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs
AU2005204685B2 (en) * 2004-01-07 2007-06-21 E-L Management Corporation Cosmetic composition and method for retarding hair growth
WO2005094804A1 (en) * 2004-03-25 2005-10-13 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
US20110091552A1 (en) * 2007-08-31 2011-04-21 Mccaffrey Tim Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions
CN101883486B (zh) * 2007-10-01 2014-09-17 阿森达治疗学股份有限公司 制备r-棉酚l-苯丙氨醇二烯胺的方法
CN104845532B (zh) 2009-06-22 2017-10-03 嘉柏微电子材料股份公司 化学机械抛光组合物以及用于抑制多晶硅移除速率的方法
KR101723699B1 (ko) 2009-07-29 2017-04-05 테이진 카세이 가부시키가이샤 폴리카보네이트-폴리디오르가노실록산 공중합체
CN101810577B (zh) * 2010-05-06 2011-09-07 山东大学 治疗肿瘤的棉酚静脉注射脂肪乳剂
CN103467538B (zh) * 2012-05-29 2015-08-19 武汉大学 具有抗艾滋病毒活性的棉酚衍生物及其制备方法
US9750761B2 (en) * 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
US20220162561A1 (en) * 2019-04-04 2022-05-26 Nissan Chemical Corporation Composition for promoting secretion of extracellular vesicles
CN110559449B (zh) * 2019-10-22 2022-09-02 长治医学院 一种聚棉酚前药胶束及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5780675A (en) * 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5936120A (en) * 1997-12-10 1999-08-10 University Of New Mexico Deoxygossylic compounds
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用

Also Published As

Publication number Publication date
JP2005502579A (ja) 2005-01-27
CN1529590A (zh) 2004-09-15
US6608107B2 (en) 2003-08-19
US20020137801A1 (en) 2002-09-26
EP1343487A2 (en) 2003-09-17
AU2002230888A1 (en) 2002-06-24
CN100490791C (zh) 2009-05-27
WO2002047673A3 (en) 2003-01-03
WO2002047673A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
BR0309396A (pt) Uso de ciclopamina no tratamento de psorìase e outros distúrbios da pele
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
NZ606825A (en) Methods and compositions for treating complement-associated disorders
IL189546A0 (en) Therapy for the treatment of disease
WO2005091991A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
WO2007089611A3 (en) Compositions and their uses directed to huntingtin
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
WO2022020114A3 (en) Methods for the prevention and treatment of hearing loss
MXPA06001286A (es) Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter.
TW200515914A (en) Compositions containing an active fraction isolated from Lycium barbarum and methods of using the same
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization
MX367580B (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.
TW200515915A (en) Extract of Trapa natans and methods of using the same